Evidence map›Paper›PMID 38269311›Full record

ArticleRespirology case reports2024

Successful dabrafenib and trametinib combination therapy in a patient with recurrent

Eriko Nakamura, Masahide Ota, Ryosuke Matsuda, Maiko Takeda, Tomomi Fujii, Yoshifumi Yamamoto, Shigeto Hontsu, Motoo Yamauchi, Masanori Yoshikawa, Shigeo Muro

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Respirology case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Eriko NakamuraDepartment of Respiratory Medicine Nara Medical University Kashihara Japan.ORCID https://orcid.org/0000-0003-0913-2475
Masahide OtaDepartment of Respiratory Medicine Nara Medical University Kashihara Japan.
Ryosuke MatsudaDepartment of Neurosurgery Nara Medical University Kashihara Japan.
Maiko TakedaDepartment of Diagnostic Pathology Nara Medical University Kashihara Japan.
Tomomi FujiiDepartment of Diagnostic Pathology Nara Medical University Kashihara Japan.
Yoshifumi YamamotoDepartment of Respiratory Medicine Nara Medical University Kashihara Japan.
Shigeto HontsuDepartment of Respiratory Medicine Nara Medical University Kashihara Japan.
Motoo YamauchiDepartment of Respiratory Medicine Nara Medical University Kashihara Japan.
Masanori YoshikawaDepartment of Respiratory Medicine Nara Medical University Kashihara Japan.
Shigeo MuroDepartment of Respiratory Medicine Nara Medical University Kashihara Japan.ORCID https://orcid.org/0000-0001-7452-9191
Nara Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There have been several reports of drug-induced lung injury caused by molecular-targeted agents. Additionally, medical history of interstitial lung disease and chest irradiation are established risk factors for the development and progression of drug-induced lung injury. Moreover, the presence of fibrosis on chest computed tomography before treatment is a predictive factor for the appearance of pneumonia induced by anticancer drugs. Accordingly, patients with a history of interstitial lung disease or pneumonitis were excluded from clinical trials of dabrafenib and trametinib combination therapy for patients with previously treated

Indexed as

BRAFdabrafenibnon‐small‐cell lung cancerradiation pneumonitistrametinib

Identifiers

PMID38269311
PMCPMC10807985
OpenAlexW4391188535

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.